NCT01543971 - Safety and Efficacy of TXA127 and Neupogen to Increase Peripheral Blood Stem Cells (PBSCs) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

March 31, 2010

Conditions

Miscellaneous Peripheral Blood Cell Abnormalities

Interventions

DRUG

TXA127

TXA127 : 300mcg/kg per day for 5 days, injection

DRUG

Neupogen (filgrastim)

Neupogen : 10mcg/kg per day for 5 days, injection

Trial Locations (1)

Charles River Clinical Servies Norhtwest, Tacoma